Prurigo Nodularis (PN) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Prurigo Nodularis (PN) Market Outlook

Thelansis’s “Prurigo Nodularis (PN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Prurigo Nodularis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Prurigo Nodularis (PN) Overview

Prurigo Nodularis (PN) is a skin disorder characterized by the formation of firm, itchy nodules on the skin's surface. The intense itching (pruritus) associated with PN often prompts individuals to scratch excessively, leading to bleeding or discomfort and potentially exacerbating the condition by inducing additional skin lesions. The underlying pathophysiology of PN has been a subject of debate, with chronic or recurrent mechanical trauma or vigorous frictional pressure believed to induce epidermal hyperplasia, resulting in skin thickening. Diagnosing Prurigo nodularis primarily relies on clinical observation. Patients typically present with a history of persistent and severe itching, along with excoriations and flesh-colored or pink nodular lesions predominantly on extensor surfaces. Dermoscopy can be a valuable diagnostic aid, particularly in distinguishing PN from other dermatological conditions. Various topical treatments are available for managing Prurigo nodularis, including potent topical corticosteroids, intralesional corticosteroids, topical calcineurin inhibitors, topical capsaicin, and topical vitamin D analogs. Additionally, phototherapy options such as PUVA (psoralen combined with ultraviolet A) therapy, including bath or topical PUVA, long-wavelength ultraviolet A, narrowband ultraviolet B, and monochromatic excimer light of 308 nm, have demonstrated efficacy in improving PN nodules.

• According to epidemiological studies, Prurigo nodularis is relatively rare, with a prevalence estimated at 72 per 100,000 among US adults aged 18 to 64 with healthcare insurance.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: